Last edition
News about "Glioblastoma"
National Institute for Health and Care Research announces first Tessa Jowell AHP Research Fellows to advance neuro-oncology research, addressing rehabilitation and supportive care gaps for brain tumour patients across the United Kingdom.
Glioblastoma | 10/03/2026 | By News Bureau
Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Glioblastoma | 05/03/2026 | By Akanki
Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Glioblastoma | 05/03/2026 | By Akanki
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
Glioblastoma | 20/12/2025 | By News Bureau | 141
Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax
Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.
Glioblastoma | 05/12/2025 | By Dineshwori | 521
Rznomics Liver Cancer Drug RZ-001 Secures Fast Track Designation from US FDA
Rznomics' anticancer drug RZ-001 has received Fast Track Designation from the US FDA for the treatment of liver cancer – Hepatocellular Carcinoma (HCC), marking its second designation after Glioblastoma (GBM), to accelerate its clinical development.
Glioblastoma | 19/02/2025 | By Abha | 265
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy